Metachip by ConquerX

Defining the next curve in early cancer detection


ConquerX's Metachip technology represents a game-changing approach to cancer diagnostics and screening by leveraging a new class of biomarkers - microRNAs - to earlier detect up to eighteen types of cancer in one accurate, cost-effective blood test.

The Problem

Cancer kills 8 million people around the world every year, and 14 million more will develop the disease. In the US, one in five people will die of some type of cancer. Cancer does not discriminte: it strikes young and old, neighbors and friends, fathers and mothers.

One-third of these deaths can be averted by routine screening and early detection of the cancer when it is most treatable. Unfortunately, with a few exceptions, there is no accurate, minimally-invasive, cost-effective and portable method to early detect the majority of cancers, including the more lethal types such as brain, ovarian or pancreatic cancer.

Metachip

The MetaChip is an optimized electrochemical biosensor that use blood sample to detect microRNAs linked to eighteen types of cancer.



Lung

Pancreas

Breast

Kidney

Bladder

Liver

Prostate

Esophangus

Gastric

Colon

Cervix

Glioblastoma

Ovary

Thyroid

Hepatocellular

Oral

KSHV

NHLs

MicroRNAs

MicroRNAs (miRNAs) are small, noncoding RNA sequences of about 18-22 nucleotides (1). They influence important cancer-related processes such as proliferation, cell cycle control, apoptosis, differentiation, migration and metabolism (2–8). In addition, miRNA expressions correlate with clinical and biological characteristics of tumours, including tissue type, differentiation, aggression and response to therapy (9,10). These characteristics, coupled with the stability of miRNAs in blood, serum, saliva, tears and other types of body fluids, make them an excellent candidate to serve as cancer biomarkers (2–8).

Because of the small amount of circulating miRNAs and the large amount of proteins in blood, miRNA extraction and quantification is technically challenging (11). Current microRNA detection methods have either low throughput, low sensitivity, are costly, require a large amount of total RNA or/and often involve laborious sample handling protocols that cannot be performed without highly trained personnel (12–14). Such limitations severely hinder the application of existing miRNA detection methods into clinical practice. With proprietary electrochemical biosensor technology, the Metachip can overcome these limitations.

Metachip workflow

The Metachip workflow has three simple steps: draw blood, place the blood on the Metachip, and put the Metachip on a portable sensor-reader to get results in 15 minutes.

Blood Sampling

Metachip Analysis

Results

References

  1. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(February):102–14.
  2. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol [Internet]. 2014;15(July):509–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25027649
  3. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell [Internet]. 2009 Jan 9 [cited 2012 Oct 27];136(1):26–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19135886
  4. Nelson PT, Wang WX, Rajeev BW. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008;18:130–8.
  5. Hébert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009;32(March):199–206.
  6. Shen J, Stass S a, Jiang F. MicroRNAs as Potential Biomarkers in Human Solid Tumors. Cancer Lett [Internet]. Elsevier Ireland Ltd; 2012 Nov 26 [cited 2012 Dec 4];(December). Available from: http://www.ncbi.nlm.nih.gov/pubmed/23196059
  7. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol [Internet]. Elsevier B.V; 2012 Oct 9 [cited 2012 Nov 13];6(6):590–610. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23102669
  8. Cissell K a, Deo SK. Trends in microRNA detection. Anal Bioanal Chem [Internet]. 2009 Jun [cited 2012 Nov 1];394(4):1109–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19367400
  9. Calin G a, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(November):857–66.
  10. Chen B, Li H, Zeng X, Yang P, Liu X, Zhao X, et al. Roles of microRNA on cancer cell metabolism. J Transl Med [Internet]. Journal of Translational Medicine; 2012 Jan [cited 2014 Feb 23];10(1):228. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3563491&tool=pmcentrez&rendertype=abstract
  11. Brase JC, Wuttig D, Kuner R, Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer [Internet]. BioMed Central Ltd; 2010;9(1):306. Available from: http://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-306
  12. Ren Y, Deng H, Shen W, Gao Z. A highly sensitive and selective electrochemical biosensor for direct detection of microRNAs in serum. Anal Chem. 2013;85:4784–9.
  13. Yin H, Zhou Y, Zhang H, Meng X, Ai S. Electrochemical determination of microRNA-21 based on graphene, LNA integrated molecular beacon, AuNPs and biotin multifunctional bio bar codes and enzymatic assay system. Biosens Bioelectron [Internet]. Elsevier B.V.; 2012;33(1):247–53. Available from: http://dx.doi.org/10.1016/j.bios.2012.01.014
  14. Wang Z, Zhang J, Guo Y, Wu X, Yang W, Xu L, et al. A novel electrically magnetic-controllable electrochemical biosensor for the ultra sensitive and specific detection of attomolar level oral cancer-related microRNA. Biosens Bioelectron [Internet]. Elsevier; 2013;45:108–13. Available from: http://dx.doi.org/10.1016/j.bios.2013.02.007

Company Address:

ConquerX

residents at MassChallenge
21 Drydock Avenue, 610E
Boston MA 02210
USA